Most patients with aggressive' non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) relapsing or resistant to front line chemotherapy have a poor prognosis (De Vita et al., 1989; Cabanillas et al., 1990; Longo, 1990) . Although good initial responses have been reported with several salvage regimens, toxicity is significant and long term disease free survival low (Cabanillas et al., 1982; Cabanillas et al., 1987; Velasquez et al., 1988; Hagemeister et al., 1987; Santoro et al., 1986) . There is therefore a requirement for more effective low toxicity regimens. In an attempt to meet this need we devised a new salvage chemotherapy combination which includes etoposide, prednisolone, ifosfamide and cisplatin (EPIC). These drugs have different mechanisms of action (Achterrath et al., 1982; Colvin, 1982; Zwelling & Kohn, 1979; Plooy et al., 1984) . The biological rationale for this schedule is derived from the single agent activity of these drugs in lymphoma, (Cavalli et al., 1981; Rodriguez et al., 1978; Taylor et al., 1982 ) the in vitro and in vivo data suggesting synergy between them (Achterrath et al., 1982; Schabel et al., 1979; Dewinko et al., 1976; Frei et al., 1988; Goldin, 1982; Durand & Goldie, 1987) and the lack of cross resistance between cisplatin and drugs used in first line combinations (Schabel et al., 1979) . Also there is evidence of incomplete cross resistance between ifosfamide and cyclophosphamide (Hilgard et al., 1983) .
Clinical benefits have been reported with the use of these drugs in different schedules (Judson & Wiltshaw, 1985; Scheulen et al., 1983) . Furthermore, investigators at the MD Anderson Hospital have demonstrated that in relapsed and resistant lymphoma the substitution of etoposide for vincristine in a combination which also included ifosfamide and methotrexate increased the CR rate from 17% to 37% (Cabanillas et al., 1982; Cabanillas et al., 1980) . Similarly the addition of 100 mg m2 cisplatin to the ESA schedule (etoposide, Methylprednisolone, cytarabine) raised the overall response rate from 38% to 69% . Therefore the clinical evidence supports the experimental data indicating activity and at least an additive effect of these drugs in relapsed and resistant lymphoma.
In this study we describe our experience with the EPIC protocol in the management of these patients.
Patients and methods

Patient selection
Thirty-two patients with NHL and 10 with HD were enrolled into this trial between November 1989 and March 1991.
Eligibility criteria included the following: (1) biopsy proven relapsing or resistant NHL or HD; (2) measurable disease; (3) informed consent; (4) EDTA > 60 ml min-'. Response to prior chemotherapy was defined according to WHO criteria (Miller et al., 1981 parametric test as indicated, and their independent effect was tested using the logistic regression model (Lehmann, 1959 Chemotherapy was delayed if white cell count < 2,000 ul or platelets <100,0001l-' on day one. Cimetidine, cotrimoxazole and antifungal prophylaxis with oral nystatin and amphotericin were given throughout the treatment. The response to EPIC and toxicity were determined using the WHO criteria (Miller et al., 1981) .
Statistical analysis Time to treatment failure (TTF; time to relapse, progression or death) and duration of survival were calculated from the beginning of treatment. Survival curves were estimated by the method of Kaplan and Meier (Peto et al., 1977) . The Log rank test was utilised to compared differences in survival and TTF (Peto et al., 1977) . The proportional hazards model was used to determine the independence of factors for survival (Cox, 1972 Toxicity and chemotherapy The EPIC regimen was generally well tolerated. A total of 150 courses of treatment were given to 42 patients, with a median 3 (1-8) cycles. The most frequent significant sideeffect was myelosuppression (see Table III ). Forty episodes of WHO grade 4 leucopenia (WBC 10001tl-') were found in 23 patients. Delay of therapy usually due to myelosuppression or infection, occurred in 20 patients with a median delay of 2 weeks per patient. Twelve episodes of fever with neutropenia (8%) were recorded, including three that were severe (WHO grade 3). Two non-disseminated Herpes-Zoster infections were also found. Alopecia was almost universal. Nausea and vomiting were usually moderate, only one patient developing WHO grade 3 toxicity. Mucositis was rare and haemorrhagic cystitis was not found in our patients. Two patients had reversible impairment of renal function and cisplatin was omitted in one and two courses respectively. The dose of etoposide was reduced by 25% in two patients (Philip et al., 1987) . Moreover, long term disease free survival is around 20% in non selected groups of patient, (Takvorian et al., 1987; Appelbaum et al., 1987; Phillips et al., 1990) results not much better than those achieved with conventional salvage therapy alone. This indicates that in relapsed NHL, intensive chemotherapy with ABMT only has a place in patients who have sensitive disease and low tumour burden after salvage therapy (Philip et al., 1987; Takvorian et al., 1987) . In patients achieving CR with salvage chemotherapy the advantage of intensive chemotherapy is not clear and the results of ongoing trials, such as the Parma study, are eagerly awaited (Philip et al., 1991) . Patients achieving only a PR with a second line chemotherapy have a very poor prognosis, and should probably be offered intensive therapy with ABMT in an attempt to achieve long term remissions.
Another approach is to overcome drug resistance by infusional therapy with doxorubicin and vincristine or by the addition of a P-170 glycoprotein blocking agent to those combinations (Chabner & Wilson, 1991 (Miller et al., 1991) .
The EPIC regimen is an attempt to develop a new chemotherapy combination for relapsed and resistant lymphoma non cross resistant with first line regimens. The results of several such combinations have been published (see Table IV ). Of particular interest are the series of trials by the MD Anderson Hospital Group. When comparing these regimens in terms of response it is clearly crucial to be mindful of the difference in case selection (Press et al., 1991) . Patients with primary resistant lymphomas and resistant relapse do particularly badly (Cabanillas et al., 1982; Cabanillas et al., 1987; Philip et al., 1987; Takvorian et al., 1987; Appelbaum et al., 1987; Phillips et al., 1990) . Several othe prognostic features for relapsed lymphoma have been reported. These include the duration of response to first line chemotherapy (Cabanillas et al., 1982) elevated serum LDH, (Cabanillas et al., 1987; Velasquez et al., 1988; Press et al., 1991) presence of bulky disease (Cabanillas et al., 1987) , number of sites of disease (Cabanillas et al., 1987) and tumour burden . For HD the duration of initial remission, presence of extranodal disease, LDH level, haemoglobin and number of prior relapses influence the outcome in patients treated with first line chemotherapy . In the IMVP-16 (ifosfamide, methotrexate and VP-16) trial a response rate of 62% with an impressive CR of 37% was obtained in 52 patients (Cabanillas et al., 1982) . However their groups of patients had better prognostic factors that the patients in this study. For example, the CR to prior chemotherapy was 40% vs 23% in our group and the duration of response to that therapy was greater than 6 months in 60% of their patients, but in only 14% of ours. The addition of methyl GAG (the MIME protocol) did not improve the response but increased the toxicity (Cabanillas et al., 1987) . With the DHAP regimen, a combination of dexamethasone, high dose Ara-C and cisplatin, the MD Anderson group achieved an overall response rate of 57.7% with a CR rate of 31% . Unfortunately, toxicity was severe with a toxic death rate of 17%. This group of 90 patients also had slightly better prognostic features than our group; 48% had achieved a CR with previous chemotherapy. It is of interest that all CR but one were observed in patients with low tumour burden. The results' obtained with the DHAP regimen have been confirmed by others (Philip et al., 1991; Press et al., 1991) . Goss et al. with the DICE regimen (dexamethasone, ifosfamide, cisplatin, etoposide) which is similar to EPIC, achieved a CR in 27% of their patients, but with greater toxicity (Goss et al., 1991) .
While seven of nine (78%) patients with HD had a PR, none achieved a CR. The analysis is confounded by the subsequent use of high dose chemotherapy and ABMT in three of the seven responding patients before a maximum response was achieved. As previously stated, a third of the patients had prior high dose chemotherapy and ABMT. In one of them EPIC had to be stopped after one course due to marrow failure, the other two attained a PR. Other investigators have obtained CR in 13%-44% of patients relapsing after MOPP and ABVD type combinations Santoro et al., 1986; Pfeundschuh et al., 1987; Tseng et al., 1987) . Of particular interest are the results of the Italian (Santoro et al., 1986) and German (Pfreundschuh , 1987) groups, who achieved good CR (40 and 44% respectively) with low toxicity in patients with poor prognostic features. Published follow up is short, however. Results of intensive therapy in these patients are promising (Vose et al., 1990) . The EPIC regimen was associated with manageable toxicity in our group of heavily pretreated patients. There were no toxic deaths and the low incidence of febrile episodes associated with neutropenia in our group (8%) compares favourably with the other regimens (Cabanillas et al., 1982 , Cabanillas et al., 1987 Velasquez et al., 1988; Phillips et al., 1990; Press et al., 1991; Goss et al., 1991; Huijgens et al., 1988; Nichols et al., 1988) . Prophylactic cotrimoxazole may have contributed to this low infection rate and absence of mortality.
The poor outcome in the transformed group of lymphomas has been previously found by some (Armitage et al., 1981) but not by other authors (Acker et al., 1983) .
Dose intensity is an accepted aim in the treatment of aggressive lymphomas and has been related to relapse free survival (De Vita et al., 1988) . There is evidence suggesting a steep dose-response relationship for cisplatin (Drewinko et al., 1973; Ozols et al., 1984; Ozols et al., 1985; Levin & Hryniuk, 1987) . However a study in advanced germ cell tumour proved that doubling the dose of cisplatin (from 20 mg m-2 for five consecutive days to 40 mg m-2) did not improve the outcome (Nichols et al., 1991) . Cisplatin toxicity on the other hand increases with higher doses (Drewinko et al., 1973; Roelofs et al., 1984; Campbell et al., 1983; Kelsen et al., 1985; Reddel et al., 1982) and with increasing cumulative dose (Roelofs et al., 1984; Dominici et al., 1989) . The method of drug administration is also important (Drewinko et al., 1973; Roelofs et al., 1984; Posner et al., 1986) . Doses up to 200 mg m-2 per course, either as a daily bolus for 5 days or by continuous infusion have been given with an important but acceptable increase in toxicity (Ozols et al., 1985; Dominici et al., 1989; Ozols et al., 1988) . We have used an intermediate cisplatin dose (60 mg m-2 per course). Other investigators have used 100 mg m-2 per course, either as a continuous one day infusion Cabanillas et al., 1988; Philip et al., 1991; Press et al., 1991) or a daily bolus for 4-5 days (Goss et al., 1991; Nichols et al., 1988) . The response rates and survival in these trials are similar. It thus remains unproved that moderate increase in cisplatin dose intensity results in a greater response rate and survival in lymphoma.
Long term disease free survival in patients with resistant or relapsed aggressive lymphomas treated with conventional chemotherapy is extremely low. Efforts should probably be directed towards improving the results of first line treatments in patients with poor prognostic features. EPIC stands as a second line chemotherapy regimen with a good overall response rate and a low toxicity profile and could be a useful combination for cytoreduction prior to high dose chemotherapy. The search for a satisfactory regimen for resistant disease needs to be continued.
Dr Hickish is a CRC funded Senior Registrar and Dr Cunningham was a CRC funded Senior Lecturer.
